ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate
(MedPage Today) -- Most patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI) had an objective response with zidesamtinib (Jideytro), according to...
A groundbreaking lung cancer medication targeting ROS1 has demonstrated a remarkable 90% response rate in patients who had never been treated with a tyrosine kinase inhibitor (TKI), according to updated findings from a phase I/II trial. Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center, presenting at the World Conference on Lung Cancer in Seoul, reported a 94% objective response rate over a median follow-up of 15.2 months.
The response persisted for at least 6, 9, and 12 months in 96%, 94%, and 86% of patients, respectively, with no median progression observed at these intervals. Among 10 patients with CNS involvement, all exhibited an intracranial response, with 100% achieving a complete response. No CNS progression occurred among patients without pre-existing brain metastases, underscoring the drug's efficacy in this critical area.
Dr. Drilon emphasized that these results support the consideration of zidesamtinib as a frontline therapy for TKI-naive patients, potentially paving the way for a supplemental FDA application to expand its use in the first line of treatment.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
